Pfizer blows off fee deadline; Roche plan to elevate CEO miffs shareholders;

@FiercePharma: Pay-for-delay to get Supreme Court consideration. News | Follow @FiercePharma

> Pfizer ($PFE) appears to be shirking its resposibility for paying its share of the $50M 'backlog' fee required under the Generic Drug User Fee Amendments (GDUFA ) law. Item

> Boehringer Ingelheim Pharmaceuticals says new study results show that major bleeding outcomes with its Pradaxa blood thinner treated with standard clinical methods appear to be better than warfarin bleeding events. Release

> Specialty pharmaceutical company Meda bought the non-sedating OTC sleep aid, MidNite, in the U.S. for an undisclosed amount of money. Item

> The mother of a 7-year-old Springfield girl has filed a lawsuit alleging that she suffered a birth defect because Pfizer ($PFE) didn't provide sufficient warning about the dangers of taking its antidepressant Zoloft. Story

> GlaxoSmithKline ($GSK) and Vodofone are linking up in Africa to see if text messaging can be used to boost childhood vaccination rates. Story

> Lucentis has been OK'd in Scotland for treating patients with vision impairment as a result of diabetic macular oedema (VI-DMO), Novartis ($NVS) announced today. Item

Medical Device News

 @FierceMedDev: A Finnish company won CE mark status for non-invasive magnetic stimulation to treat major depression. News | Follow @FierceMedDev

@MarkHFierce: GE has clearly wanted Insightec for a long time. The Israeli company uses MRI-guided ultrasound to ablate tissue. Release | Follow @MarkHFierce

 @DamianFierce: Covance says its the first global CRO to get GLP certification from Chinese regulators. More | Follow @DamianFierce

> Report: Sanofi considering Bayer's glucose meter unit. Article

> Brain stimulation anti-depression device gets CE marking. Item

> Vela Diagnostics licenses Swift Biosciences cancer detection tech. News

Biotech News

 @FierceBiotech: Piramal continues market access blitz with Abacus takeover. Story | Follow @FierceBiotech

@JohnCFierce: Isis gets a $30M upfront in a new pact with Biogen to develop antisense drugs. $200M per in biobucks. News | Follow @JohnCFierce

 @RyanMFierce: Wow. Amgen buying deCode for $415M. Wants to validate disease targets for drug development. | Follow @RyanMFierce

> Biogen embraces Isis again in early-stage collaboration worth up to $630M. Story

> ASH roundup: Pharmacyclics' ibrutinib seizes center stage with more promising leukemia results. Report

> Takeda's oral successor to Velcade benefits blood cancer patients. News

Biotech IT News

> Consortium sifting through MS data to find new endpoint. Report

> Piramal continues market access blitz with Abacus takeover. News

> Internet advocate slams pharma's social media moves. Story

> Survey: Pharma's social media, mobile use spreads in 2012. Article

CRO News

> Recipharm bets on analytical development with expansion. More

> Covance notches GLP nod from Chinese regulators. Report

> Alimera taps Quintiles to commercialize Iluvien. News

> AMRI re-ups with GE Healthcare, its largest supply partner. Story

And Finally... The plan by the board of directors of Roche ($RHHBY) to elect CEO Severin Schwan chairman of the board and dump two independent directors has raised the hackles of some shareholders. Story
 

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.